Canadian biotech firm Arius Research has chosen Ireland's Fusion Antibodies as the beneficiary of a new antibody engineering deal. Under the terms of the agreement, Fusion Antibodies will use its novel technology to make new recombinant antibodies for Arius' pipeline of anti-cancer compounds, which it is currently expanding. No other details were disclosed. Fusion's technology platform, called Fusion Expression Technologies (FET) is a parallel tracking system that allows the analysis of over 500 potential protein targets or antibodies simultaneously, monitoring how different conditions, such as temperature and pH, can affect them. "This contract is strategically important, giving us an opportunity to work with a company that has an extensive network of partners in biotechnology throughout North America, for the development of innovative therapies for many types of cancer," said Dr Simon Douglas, Fusion's CEO. In other news, small US biotech, Samaritan Pharmaceuticals, has enlisted the help of Indian firm Advinus Therapeutics to perform validating preclinical studies for its lead Alzheimer's disease (AD) drug. Advinus will perform studies to validate Samaritan's findings in previous preclinical trials, which suggest that the drug, called caprospinol (SP-233), directly targets the amyloid peptide. Amyloid plaques are now thought to be a significant factor in the development of AD. Samaritan plans to use the extra data gathered by Advinus to bolster its efforts to out-license caprospinol to a big pharma firm, while concurrently launching an investigational new drug application (IND) with the Food and Drug Administration (FDA). "After a long and extensive search for the right contract research organisation (CRO) to perform preclinical studies, we found Advinus," said Dr Greeson, CEO of Samaritan Pharmaceuticals. "This outsourcing research and development agreement will allow us to focus more on drug discovery; as well as, out-licensing and expeditiously advancing our Alzheimer's drug through the FDA drug development path."